Dr. Keller is a clinician-investigator who provides care to children and adults with congenital heart disease throughout Kentucky. He is also an expert in the causes of congenital heart disease and in the development and testing of novel technologies for children and adults with heart disease. On March 1, 2020, Dr. Brad Keller joined the Cincinnati Children's Heart Institute and Dr. Juan Villafañe, as co-director of Cincinnati Children’s Heart Institute – Greater Louisville and Western Kentucky practices, and is at our offices throughout the region. He brings more than 30 years of clinical and administrative congenital heart care experience including prior roles as division chief of Pediatric Cardiology at the University of Kentucky and at the Children’s Hospital of Pittsburgh.
Pediatric Cardiology Fellowship: University of Rochester Medical Center, Rochester, NY, 1988-1991.
Pediatric Residency: Johns Hopkins Hospital, Baltimore, MD, 1985-1988.
MD: Pennsylvania State University School of Medicine, Hershey, PA, 1981-1985.
BS: University of Pennsylvania, Philadelphia, PA, 1977-1981.
Pediatric and adult congenital heart disease
Adolescent and Adult Congenital Heart Disease, Heart Institute, Cardiology Clinic
Clinical translation of outpatient telemedicine
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Right Heart Catheterization in Pediatric Pulmonary Arterial Hypertension: Insights and Outcome from a Large Tertiary Center. Journal of Clinical Medicine. 2022; 11.
Sulforaphane Does Not Protect Right Ventricular Systolic and Diastolic Functions in Nrf2 Knockout Pulmonary Artery Hypertension Mice. Cardiovascular Drugs and Therapy. 2022; 36:425-436.
Isolated Coarctation of the Aorta: Current Concepts and Perspectives. Frontiers in Cardiovascular Medicine. 2022; 9.
Pulmonary hypertensive crisis in children with pulmonary arterial hypertension undergoing cardiac catheterization. Pulmonary Circulation. 2022; 12.
Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways. Acta Pharmaceutica Sinica B. 2022; 12:708-722.
Emerging roles of microRNA-208a in cardiology and reverse cardio-oncology. Medicinal Research Reviews. 2021; 41:2172-2194.
Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension. CJC open. 2021; 3:872-879.
Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy. Acta Pharmacologica Sinica. 2021; 42:932-941.
Zinc as a countermeasure for cadmium toxicity. Acta Pharmacologica Sinica. 2021; 42:340-346.
Successful outcomes for atrial septal defect associated with pulmonary arterial hypertension using a “treat-repair-treat” strategy. International journal of cardiology congenital heart disease. 2021; 2.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey